| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Livmoniplimab
CAS:2412004-88-5
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Livmoniplimab
CAS:2412004-88-5
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Livmoniplimab
CAS:2412004-88-5
Purity:>95% Package:100ug;200ug;1mg
|
|
| | Livmoniplimab Basic information |
| Product Name: | Livmoniplimab | | Synonyms: | Livmoniplimab;Research Grade Livmoniplimab (DHB91603);Research Grade Livmoniplimab | | CAS: | 2412004-88-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Livmoniplimab Structure]() |
| | Livmoniplimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Livmoniplimab Usage And Synthesis |
| Uses | Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors[1][2]. | | in vivo | Livmoniplimab (250 μg; three times a week; 3 weeks; i.p.) exhibits anti-tumor activity in colon cancer mice[2]. | Animal Model: | 7-week-old female B-hGARP mice subcutaneously inoculated with MC38 mouse colon cancer cells[2]. | | Dosage: | 250 μg | | Administration: | Intraperitoneal injection (i.p.); three times a week; 3 weeks | | Result: | Resulted in 34.3% tumor growth inhibition. |
| | References | [1] Tindall RR, et al. The TGF-β superfamily as potential therapeutic targets in pancreatic cancer. Front Oncol. 2024 Mar 4;14:1362247. DOI:10.3389/fonc.2024.1362247
[2] Guo J, et al. A novel GARP humanized mouse model for efficacy assessment of GARP-targeting therapies. Int Immunopharmacol. 2024 Mar 30;130:111782. DOI:10.1016/j.intimp.2024.111782 |
| | Livmoniplimab Preparation Products And Raw materials |
|